

LIST OF CONTENTS

NUMBER 1

Ten Most Popular EJC Papers	ix
In this issue	xiii
Forthcoming papers	xiv
News	1
Editorial Comment	
The two-faced keeper of gates to heaven <i>J. Smyth</i>	6
Current Perspective	
Adjuvant chemotherapy for non-small cell lung cancer: Ready for clinical practice? <i>M. Tiseo, V. Franciosi, F. Grossi and A. Ardizzoni</i>	8
Reviews	
Mutations of the epidermal growth factor receptor in non-small cell lung cancer – Search and destroy <i>S.K. Chan, W.J. Gullick and M.E. Hill</i>	17
Peripheral neuropathy: A persisting challenge in paclitaxel-based regimes <i>S. Mielke, A. Sparreboom and K. Mross</i>	24
Prevention and treatment of cancer cachexia: New insights into an old problem <i>M. Muscaritoli, M. Bossola, Z. Aversa, R. Bellantone and F.R. Fanelli</i>	31
Clinical Oncology	
Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer? <i>F. Efficace, A. Bottomley, C. Coens, K. Van Steen, T. Conroy, P. Schöffski, H. Schmoll, E. Van Cutsem and C.-H. Köhne</i>	42
Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours <i>C.N. Sternberg, P. de Mulder, J.H. Schornagel, C. Theodore, S.D. Fossa, A.T. van Oosterom, J.A. Witjes, M. Spina, C.J. van Groeningen, B. Duclos, J.T. Roberts, C. de Balincourt and L. Collette, the EORTC Genito-Urinary Cancer Group</i>	50
The development of the EORTC QLQ-C15-PAL: A shortened questionnaire for cancer patients in palliative care <i>M. Groenvold, M.Aa. Petersen, N.K. Aaronson, J.I. Arraras, J.M. Blazeby, A. Bottomley, P.M. Fayers, A. de Graeff, E. Hammerlid, S. Kaasa, M.A.G. Sprangers and J.B. Bjorner, for the EORTC Quality of Life Group</i>	55
Paediatric Oncology	
Unilateral retinoblastoma, lack of familial history and older age does not exclude germline RB1 gene mutation <i>B. Brichard, M. Heusterspreute, P. De Potter, C. Chantrain, C. Vermeylen, C. Sibille and J.-L. Gala</i>	65
Epidemiology and Cancer Prevention	
Glutathione S-transferase M1 and T1 genetic polymorphisms are not related to the risk of hepatocellular carcinoma: A study in the Spanish population <i>J.M. Ladero, C. Martínez, E. García-Martín, P. Ropero, O. Briceño, A. Villegas, M. Díaz-Rubio and J.A.G. Agúndez</i>	73
Bayesian methods for early detection of changes in childhood cancer incidence: Trends for acute lymphoblastic leukaemia are consistent with an infectious aetiology <i>M.M. Maule, L. Zuccolo, C. Magnani, G. Pastore, P. Dalmasso, N. Pearce, F. Merletti and D. Gregori</i>	78

Body mass index and colon cancer risk in Chinese people: Menopause as an effect modifier L. Hou, B.-T. Ji, A. Blair, Q. Dai, Y.-T. Gao, J.D. Potter and W.-H. Chow	84
---	----

Experimental Oncology

Targeting CD99 in association with doxorubicin: An effective combined treatment for Ewing's sarcoma K. Scotlandi, S. Perdichizzi, G. Bernard, G. Nicoletti, P. Nanni, P.-L. Lollini, A. Curti, M.C. Manara, S. Benini, A. Bernard and P. Picci	91
Endothelial cell apoptosis in the context of quantification of angiogenesis in solid human adenocarcinomas: A novel double immunolabelling technique to identify endothelial cell apoptosis K.P. de Jong, P.B. Vermeulen, E. van Marck, M. Boot and A.S.H. Gouw	97
Expression of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) as a prognostic indicator in gastric cancer S.Y. Song, H.J. Son, E. Nam, J.C. Rhee and C. Park	101
Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma J. Loeffler-Ragg, M. Witsch-Baumgartner, A. Tzankov, W. Hilbe, I. Schwentner, G.M. Sprinzl, G. Utermann and H. Zwierzina	109
Vascular endothelial growth factors and receptors in colorectal cancer: Implications for anti-angiogenic therapy S.E. Duff, M. Jeziorska, D.D. Rosa, S. Kumar, N. Haboubi, D. Sherlock, S.T. O'Dwyer and G.C. Jayson	112

Calendar of Forthcoming Meetings	I
----------------------------------	---

NUMBER 2

In this issue	xi
Forthcoming papers	xii
News	119
Editorial Comment	
Targeted kinase inhibitors in lung cancer: From EGFR to patients G. Apolone, C. La Vecchia and S. Garattini	124
Reviews	
Cancer and pregnancy: Poena magna, not anymore G. Pentheroudakis and N. Pavlidis	126
Genotyping and phenotyping cytochrome P450: Perspectives for cancer treatment R.H.J. Mathijssen and R.H.N. van Schaik	141
Borderline tumours of the ovary and fertility P. Morice	149
Clinical Oncology	
In transit/local recurrences in melanoma patients after sentinel node biopsy and therapeutic lymph node dissection P. Rutkowski, Z.I. Nowecki, Z. Zurawski, W. Dziewirski, A. Nasierowska-Guttmejer, T. Świtaj and W. Ruka	159
Prostate cancer diagnosis: The impact on patients' mental health I.J. Korfage, H.J. de Koning, M. Roobol, F.H. Schröder and M.-L. Essink-Bot	165
Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing C. Sessa, L. Viganò, G. Grasselli, J. Trigo, I. Marimon, A. Lladò, A. Locatelli, N. Ielmini, S. Marsoni and L. Gianni	171
A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: A study by the Scottish Gynaecological Cancer Trials Group (SGCTG) N.S. Reed, C.J. Poole, R. Coleman, D. Parkin, J.D. Graham, S.B. Kaye, J. Ostrowski, I. Duncan, J. Paul and A. Hay	179

Serum EGFR levels and efficacy of trastuzumab-based therapy in patients with metastatic breast cancer G. Hudelist, W.J. Köstler, D. Gschwantler-Kaulich, K. Czerwenka, E. Kubista, R. Müller, S. Helmy, M. Manavi, C.C. Zielinski and C.F. Singer	186
A National Cancer Institute of Canada Clinical Trials Group Study – IND.135: Phase I/II study of irinotecan (camptosar), oxaliplatin and raltitrexed (tomudex) (COT) in patients with advanced colorectal cancer J.A. Maroun, D. Jonker, L. Seymour, R. Goel, M. Vincent, W. Kocha, C. Cripps, B. Fisher, D. Lister, A. Malpage and G. Chiritescu	193
A study from the EORTC new drug development group: Open label phase II study of sabarubicin (MEN-10755) in patients with progressive hormone refractory prostate cancer W. Fiedler, N. Tchen, J. Bloch, P. Fargeot, R. Sorio, J.B. Vermorken, L. Collette, D. Lacombe and C. Twelves	200
Paediatric Oncology	
Parenteral nutrition is not superior to replacement fluid therapy for the supportive treatment of chemotherapy induced oral mucositis in children I. Schmid, M. Schmitt, M. Streiter, R. Meilbeck, M.H. Albert, D. Reinhardt and D. Stachel	205
Epidemiology and Cancer Prevention	
Ultraviolet B sensitivity of peripheral lymphocytes as an independent risk factor for cutaneous melanoma R. Pedeux, F. Sales, J. Pourchet, M. Kallassy, C. Fayolle, M. Boniol, G. Severi, G. Ghanem, H.(N). Nakazawa, P. Autier and J.-F. Doré	212
Relative and absolute risk of colorectal cancer for individuals with a family history: A meta-analysis A.S. Butterworth, J.P.T. Higgins and P. Pharoah	216
Management and prognosis of esophageal cancers: Has progress been made? A.M. Bouvier, C. Binquet, A. Gagnaire, J.L. Jouve, J. Faivre and L. Bedenne	228
Cancer survival in the elderly: Effects of socio-economic factors and health care system features (ELDCARE project) M. Vercelli, R. Lillini, R. Capocaccia, A. Micheli, J.W. Coebergh, M. Quinn, C. Martinez-Garcia and A. Quaglia, The ELDCARE Working Group	234
Experimental Oncology	
Inherent pacemaker function of duodenal GIST S. Furuzono, S. Ohya, S. Inoue, A. Nakao, Y. Imaizumi and S. Nakayama	243
Identification of HNP3 as a tumour marker in CD4+ and CD4- lymphocytes of patients with cutaneous T-cell lymphoma N. Escher, B. Spies-Weißhart, M. Kaatz, C. Melle, A. Bleul, D. Driesch, U. Wollina and F. von Eggeling	249
Prognostic significance of combined expression of MUC1 and adhesion molecules in advanced gastric cancer T. Ohno, R. Aihara, Y. Kamiyama, E. Mochiki, T. Asao and H. Kuwano	256
Expression of death-associated protein kinase during tumour progression of human renal cell carcinomas: Hypermethylation-independent mechanisms of inactivation N. Wethkamp, U. Ramp, H. Geddert, W.A. Schulz, A.R. Florl, C.V. Suschek, M. Hassan, H.E. Gabbert and C. Mahotka	264
Calendar of Forthcoming Meetings	I

NUMBER 3

In this issue	xii
Forthcoming papers	xiii
News	275
Editorial Comment	
The 'Lost Tribe' and the need for a promised land: The challenge of cancer in teenagers and young adults M.C.G. Stevens	280

Reviews

Efficacy of homeopathic therapy in cancer treatment S. Milazzo, N. Russell and E. Ernst	282
Key cancer cell signal transduction pathways as therapeutic targets R. Bianco, D. Melisi, F. Ciardiello and G. Tortora	290
Prognostic significance of multidrug resistance-related proteins in childhood acute lymphoblastic leukaemia K. Swerts, B. De Moerloose, C. Dhooge, G. Laureys, Y. Benoit and J. Philippé	295
Mechanisms of pericyte recruitment in tumour angiogenesis: A new role for metalloproteinases C.F. Chantrain, P. Henriot, S. Jodele, H. Emonard, O. Feron, P.J. Courtoy, Y.A. DeClerck and E. Marbaix	310

Clinical Oncology

Randomized evidence on chemotherapy and hormonal therapy regimens for advanced endometrial cancer: An overview of survival data N.P. Polyzos, N. Pavlidis, E. Paraskevaidis and J.P.A. Ioannidis	319
Quality of life in long-term Hodgkin's disease survivors with chronic fatigue M.J. Hjermstad, L. Oldervoll, S.D. Fosså, H. Holte, A.B. Jacobsen and J.H. Loge	327
The experiences of men with breast cancer in the United Kingdom R. Iredale, K. Brain, B. Williams, E. France and J. Gray	334
Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma C. Müller-Horvat, P. Radny, T.K. Eigentler, J. Schäfer, C. Pfannenberger, M. Horger, S. Khorchidi, T. Nägele, C. Garbe, C.D. Claussen and H.-P. Schlemmer	342
Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: Long-term results of European Organisation for Research and Treatment of Cancer studies G.H. de Bock, J.A. van der Hage, H. Putter, J. Bonnema, H. Bartelink and C.J. van de Velde	351
Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma A.H.S. Lee, S.E. Pinder, R.D. Macmillan, M. Mitchell, I.O. Ellis, C.W. Elston and R.W. Blamey	357
Pre-treatment proliferation and the outcome of conventional and accelerated radiotherapy G.D. Wilson, M.I. Saunders, S. Dische, F.M. Daley, F.M. Buffa, P.I. Richman and S.M. Bentzen	363
High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma A.C.J. van Akkooi, J.H.W. de Wilt, C. Verhoef, W.J. Graveland, A.N. van Geel, M. Kliffen and A.M.M. Eggermont	372

Paediatric Oncology

The two human homologues of yeast UFD2 ubiquitination factor, UBE4A and UBE4B, are located in common neuroblastoma deletion regions and are subject to mutations in tumours H. Carén, A. Holmstrand, R.-M. Sjöberg and T. Martinsson	381
---	-----

Epidemiology and Cancer Prevention

Surgical treatment of ovarian cancer in different hospital categories – A prospective nation-wide study in Finland S. Kumpulainen, T. Kuoppala, A. Leminen, J. Penttinen, U. Puistola, E. Pukkala, R. Sankila, J. Mäkinen and S. Grénman	388
Changes in multiple myeloma epidemiology in the last thirty years: A single centre experience P. Zappasodi, A. Corso, C. Klersy, G. Pica, S. Mangiacavalli, M. Varettoni, C. Rusconi, C. Pascutto and M. Lazzarino	396
Cancer survival among adolescents in France E. Desandes, B. Lacour, D. Sommelet, A. Danzon, P. Delafosse, P. Grosclaude, J. Mace-Lesech, N. Maarouf, A. Marr, N. Raverdy-Bourdon, B. Tretarre, M. Velten and L. Brugieres	403

High risk of venous thrombosis in patients with pancreatic cancer: A cohort study of 202 patients J.W. Blom, S. Osanto and F.R. Rosendaal	410
--	-----

Experimental Oncology

Cyclooxygenase-2 expression and oxidative DNA adducts in murine intestinal adenomas: Modification by dietary curcumin and implications for clinical trials R.G. Tunstall, R.A. Sharma, S. Perkins, S. Sale, R. Singh, P.B. Farmer, W.P. Steward and A.J. Gescher	415
---	-----

Celecoxib leads to G ₂ /M arrest by induction of p21 and down-regulation of cyclin B1 expression in a p53-independent manner E. Cohen-Noyman, H. Dvory-Sobol, D. Kazanov, A. Figer, S. Birkenfeld, L. Madar-Shapiro, R. Benamouzig and N. Arber	422
---	-----

Calendar of Forthcoming Meetings	I
---	---

NUMBER 4

In this issue	ix
---------------	----

Forthcoming papers	x
--------------------	---

News	427
-------------	-----

Editorial Comment

An irresistible thirst for knowledge! J.F. Smyth	432
---	-----

Position Paper

“The Art of Successful Publication” ECCO 13 Workshop Report J. Smyth, J. Verweij, M. D’Incalci and L. Balakrishnan	434
---	-----

Reviews

GLI transcription factors: Mediators of oncogenic Hedgehog signalling M. Kasper, G. Regl, A.-M. Frischauf and F. Aberger	437
---	-----

European Union centralised procedure for marketing authorisation of oncology drugs: An in-depth review of its efficiency T. Netzer	446
---	-----

Clinical Oncology

Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: A multicenter phase II study with dose adjustment according to baseline serum bilirubin level V. Boige, J. Taïeb, M. Hebbar, D. Malka, T. Debaere, L. Hannoun, E. Magherini, D. Mignard, T. Poynard and M. Ducreux	456
---	-----

Clinico-histologic parameters of osteosarcoma patients with late relapse E.I. Hauben, S. Bielack, R. Grimer, G. Jundt, P. Reichardt, M. Sydes, A.H.M. Taminiau and P.C.W. Hogendoorn	460
---	-----

Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: A safe combination R. Hoekstra, F.Y.F.L. de Vos, F.A.L.M. Eskens, E.G.E. de Vries, D.R.A. Uges, R. Knight, R.A. Carr, R. Humerickhouse, J. Verweij and J.A. Gietema	467
---	-----

Is MSI-H of value in predicting the development of metachronous colorectal cancer? D.A. Lawes, T. Pearson, S. SenGupta and P.B. Boulos	473
---	-----

Development of a disease-specific quality of life questionnaire module for patients with gastrointestinal neuroendocrine tumours A.H.G. Davies, G. Larsson, J. Ardill, E. Friend, L. Jones, M. Falconi, R. Bettini, M. Koller, O. Sezer, C. Fleissner, B. Taal, J.M. Blazeby and J.K. Ramage, On behalf of the EORTC Quality of Life Group	477
---	-----

Ets2 transcription factor in normal and neoplastic human breast tissue Y. Buggy, T.M. Maguire, E. McDermott, A.D.K. Hill, N. O'Higgins and M.J. Duffy	485
--	-----

Paediatric Oncology

Assessment of hearing in very young children receiving carboplatin for retinoblastoma C. Smits, S.J. Swen, S. Theo Goverts, A.C. Moll, S.M. Imhof and A.Y.N. Schouten-van Meeteren	492
Caring for survivors of childhood cancers: The size of the problem H.L. Curry, S.E. Parkes, J.E. Powell and J.R. Mann	501

Epidemiology and Cancer Prevention

Childhood leukaemias and CNS tumours: Correlation of international incidence rates S.J. Hepworth, R.G. Feltbower and P.A. McKinney	509
Stem cell transplantation: Risk factors for psychiatric morbidity J.M. Prieto, J. Blanch, J. Atala, E. Carreras, M. Rovira, E. Cirera and C. Gastó	514
Association between different alcoholic beverages and leukoplakia among non- to moderate-drinking adults: A matched case-control study S. Petti and C. Scully	521
Methylenetetrahydrofolate reductase 677C>T polymorphism and gastric cancer susceptibility in Mexico M. Lacasaña-Navarro, M. Galván-Portillo, J. Chen, M. López-Cervantes and L. López-Carrillo	528
Survival in France after childhood acute leukaemia and non-Hodgkin's lymphoma (1990–2000) A. Goubin, M.F. Auclerc, A. Auvrignon, C. Patte, C. Bergeron, D. Hémon and J. Clavel	534

Experimental Oncology

Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma M. Younes, G.V. Georgakis, M. Rahmani, D. Beer and A. Younes	542
Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? D. Strumberg, A. Awada, H. Hirte, J.W. Clark, S. Seeber, P. Piccart, E. Hofstra, D. Voliotis, O. Christensen, A. Brueckner and B. Schwartz	548
RARRES1 expression is significantly related to tumour differentiation and staging in colorectal adenocarcinoma C.-C. Wu, R.-Y. Shyu, J.-M. Chou, S.-W. Jao, P.-C. Chao, J.-C. Kang, S.-T. Wu, S.-L. Huang and S.-Y. Jiang	557

Calendar of Forthcoming Meetings	I
---	----------

NUMBER 5

In this issue	xiv
News	567
Editorial Comment	
Integrative oncology – What's in a name? J.F. Smyth	572
Current Perspective	
Chronomodulated chemotherapy for colorectal cancer: Failing the test of time? C.H. Takimoto	574

Reviews

- Recent developments in the use of chemotherapy in brain tumours 582
M.J. van den Bent, M.E. Hegi and R. Stupp
- Malignant ascites: Systematic review and guideline for treatment 589
G. Becker, D. Galandi and H.E. Blum
- High-throughput techniques in breast cancer: A clinical perspective 598
E. Espinosa, A. Redondo, J.Á.F. Vara, P. Zamora, E. Casado, P. Cejas and M.G. Barón

Clinical Oncology

- Randomised phase II study of standard versus chronomodulated CPT-11 plus chronomodulated 5-fluorouracil and folinic acid in advanced colorectal cancer patients 608
C. Garufi, B. Vanni, A.M. Aschelter, A.R. Zappalà, E. Bria, C. Nisticò, I. Sperduti, F. Cognetti and E. Terzoli
- Intraoperative sentinel lymph node examination by frozen section, immunohistochemistry and imprint cytology during breast surgery – A prospective study 617
F. Celebioglu, M. Sylvan, L. Perbeck, L. Bergkvist and J. Frisell
- Risk-reducing surgery in women with familial susceptibility for breast and/or ovarian cancer 621
Y. Antill, J. Reynolds, M.-A. Young, J. Kirk, K. Tucker, T. Bogtstra, S. Wong, T. Dudding, J. Di Iulio and K.-A. Phillips
- The association between Akt activation and resistance to hormone therapy in metastatic breast cancer 629
E. Tokunaga, A. Kataoka, Y. Kimura, E. Oki, K. Mashino, K. Nishida, T. Koga, M. Morita, Y. Kakeji, H. Baba, S. Ohno and Y. Maehara
- Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients 636
J. Cienas, P. Urban, W. Küng, V. Vuaroqueaux, M. Labuhn, E. Wight, U. Eppenberger and S. Eppenberger-Castori

Paediatric Oncology

- Mutational analysis of PDGFR-RAS/MAPK pathway activation in childhood medulloblastoma 646
R.J. Gilbertson, J.A. Langdon, A. Hollander, R. Hernan, T.L. Hogg, A. Gajjar, C. Fuller and S.C. Clifford

Epidemiology and Cancer Prevention

- Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers 650
R.B.B. Sade, A. Chetrit, A. Figer, M.Z. Papa, D. Flex, S. Rizel and E. Friedman
- Skin cancer in survivors of childhood and adolescent cancer 656
F. Levi, R. Moeckli, L. Randimbison, V.-C. Te, M. Maspoli and C. La Vecchia
- Time trends of incidence, mortality, and relative survival of invasive skin melanoma in Lithuania 660
A. Stang, S. Valiukeviciene, B. Aleknaviciene and J. Kurtinaitis

Experimental Oncology

- Effects of down-regulating the *Id* genes in human colorectal cancer cells on early steps of haematogenous metastasis 668
Y. Okaji, N.H. Tsuno, J. Kitayama, D. Sakurai, N. Tsuchiya, S. Saito, K. Takegami, T. Tsuchiya, K. Kawai, K. Yazawa, M. Asakage, S. Yoneyama, J. Yamada, K. Tokunaga, K. Takahashi and H. Nagawa
- Correlations between c-myc gene copy-number and clinicopathological parameters of ovarian tumours 674
I. Dimova, S. Raitcheva, R. Dimitrov, N. Doganov and D. Toncheva
- Endothelin-3 production by human rhabdomyosarcoma: A possible new marker with a paracrine role 680
A. Palladini, A. Astolfi, S. Croci, C. De Giovanni, G. Nicoletti, A. Rosolen, F. Sartori, P.-L. Lollini, L. Landuzzi and P. Nanni

Calendar of Forthcoming Meetings

NUMBER 6

Editorial F. Balkwill	689
Endometriosis as a model for inflammation–hormone interactions in ovarian and breast cancers R.B. Ness and F. Modugno	691
C-reactive protein levels and subsequent cancer outcomes: Results from a prospective cohort study K.J. Helzlsouer, T.P. Erlinger and E.A. Platz	704
<i>Helicobacter pylori</i> infection and gastric cancer T. Matysiak-Budnik and F. Mégraud	708
Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy A. Sica, T. Schioppa, A. Mantovani and P. Allavena	717
Inflammation, proteases and cancer L.C.L. van Kempen, K.E. de Visser and L.M. Coussens	728
Inflammation in epithelial skin tumours: Old stories and new ideas M.M. Mueller	735
Tumour necrosis factor- α as a tumour promoter P. Szlosarek, K.A. Charles and F.R. Balkwill	745
Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour–host interactions R.N. Apte, Y. Krelin, X. Song, S. Dotan, E. Recih, M. Elkabets, Y. Carmi, T. Dvorkin, R.M. White, L. Gayvoronsky, S. Segal and E. Voronov	751
Inflammatory chemokines in cancer growth and progression B.J. Rollins	760
Cancer CXC chemokine networks and tumour angiogenesis R.M. Strieter, M.D. Burdick, J. Mestas, B. Gomperts, M.P. Keane and J.A. Belperio	768
NF- κ B inhibition: A double-edged sword in cancer? E. Pikarsky and Y. Ben-Neriah	779
Is nuclear factor kappa-B the missing link between inflammation, cancer and alteration in hepatic drug metabolism in patients with cancer? E. Assenat, S. Gerbal-chaloin, P. Maurel, M.J. Vilarem and J.M. Pascussi	785
Therapeutic potential of cytokine and chemokine antagonists in cancer therapy L. Yan, G.M. Anderson, M. DeWitte and M.T. Nakada	793

NUMBER 7

Forthcoming papers	ix
In this issue	xi
News	803
Editorial Comment	
With a little help from small friends: Enhanced chemotherapeutic effects with imatinib S. Sleijfer	808

Position Paper

- Molecular regulation of an invasion-related molecule – options for tumour staging and clinical strategies 811
H. Allgayer

Reviews

- Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: An update based on meta-analysis 820
M.R. van Dijk, E.W. Steyerberg and J.D.F. Habbema
- Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials 827
M. Trumper, P.J. Ross, D. Cunningham, A.R. Norman, R. Hawkins, M. Seymour, P. Harper, T. Iveson, M. Nicolson and T. Hickish
- Quality of life versus prolongation of life in patients treated with chemotherapy in advanced colorectal cancer: A review of randomized controlled clinical trials 835
S.J. de Kort, P.H.B. Willemse, J.M. Habraken, H.C.J.M. de Haes, D.L. Willems and D.J. Richel
- Cancer-related fatigue: A critical appraisal 846
G. Prue, J. Rankin, J. Allen, J. Gracey and F. Cramp

Clinical Oncology

- Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours 864
S. George, J. Desai, J.P. Eder, J. Manola, D.P. Ryan, L.J. Appleman and G.D. Demetri
- Impact of an information booklet on satisfaction and decision-making about BRCA genetic testing 871
J. Mancini, C. Noguès, C. Adenis, P. Berthet, V. Bonadona, A. Chompret, I. Coupier, F. Eisinger, J.-P. Fricker, M. Gauthier-Villars, C. Lasset, A. Lortholary, T.D. N'Guyen, P. Vennin, H. Sobol, D. Stoppa-Lyonnet and C. Julian-Reynier
- A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993) 882
R.E. Coleman, L. Biganzoli, P. Canney, L. Dirix, L. Mauriac, P. Chollet, V. Batter, E. Ngulula-Kabanga, C. Dittrich and M. Piccart
- Growth hormone receptor overexpression predicts response of rectal cancers to pre-operative radiotherapy 888
X. Wu, M. Wan, G. Li, Z. Xu, C. Chen, F. Liu and J. Li
- Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study 895
M. Baum, A. Hackshaw, J. Houghton, Rutqvist, T. Fornander, B. Nordenskjöld, A. Nicolucci and R. Sainsbury, ZIPP International Collaborators' Group
- Surgeons' views on multi-disciplinary breast meetings 905
E.J. Macaskill, S. Thrush, E.M. Walker and J.M. Dixon

Paediatric Oncology

- The role of mannose-binding lectin (MBL) in paediatric oncology patients with febrile neutropenia 909
F.N.J. Frakking, M.D. van de Wetering, N. Brouwer, K.M. Dolman, J. Geissler, B. Lemkes, H.N. Caron and T.W. Kuijpers

Epidemiology and Cancer Prevention

- Head injury and brain tumours in adults: A case-control study in Rio de Janeiro, Brazil 917
G.T.R. Monteiro, R.A. Pereira, R.J. Koifman and S. Koifman
- A population-based study on the familial aggregation of cutaneous malignant melanoma in Iceland 922
B.J. Eldon, S. Thorlacius, T. Jonsson, J.G. Jonasson, J. Kjartansson, S. Bodvarsson, E. Steingrimsdóttir and T. Rafnar
- Population-mixing at the place of residence at the time of birth and incidence of childhood leukaemia in France 927
J. Rudant, B. Baccaini, M. Ripert, A. Goubin, S. Bellec, D. Hémon and J. Clavel

Experimental Oncology

Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel L.S. Faried, A. Faried, T. Kanuma, T. Nakazato, T. Tamura, H. Kuwano and T. Minegishi	934
Inhibiting myosin light chain kinase retards the growth of mammary and prostate cancer cells L.-Z. Gu, W.-Y. Hu, N. Antic, R. Mehta, J.R. Turner and P. de Lanerolle	948
Linking TP53 codon 72 and P21 nt590 genotypes to the development of cervical and ovarian cancer A.M. Santos, H. Sousa, D. Pinto, C. Portela, D. Pereira, R. Catarino, I. Duarte, C. Lopes and R. Medeiros	958
Budding invasive margin and prognosis in colorectal cancer – no direct association with β -catenin expression T.T. Hörkö, K. Klintrup, J.M. Mäkinen, J.B. Näpänkangas, H.J. Tuominen, J. Mäkelä, T.J. Karttunen and M.J. Mäkinen	964
Aberrant methylation of Fragile Histidine Triad gene is associated with poor prognosis in early stage esophageal squamous cell carcinoma E.J. Lee, B.B. Lee, J.W. Kim, Y.M. Shim, I. Hoseok, J. Han, E.Y. Cho, J. Park and D.-H. Kim	972
Activating anti-CD40 antibodies induce tumour invasion by cytotoxic T-lymphocytes and inhibition of tumour growth in experimental liver cancer E. Ryschich, A. Märten, E. Schmidt, M. Linnebacher, N. Wentzensen, S. Eisold, E. Klar, M.W. Böhler and J. Schmidt	981
Corrigendum to “Harnessing the power of information and communication technologies to meet patients’ informational needs” [EJC Supplements, 3 (2005) 479, Abstract 1662] N. Kearney	988

Calendar of Forthcoming Meetings

I

NUMBER 8

In this issue	xii
News	989
Position Paper	
Clinical applications of newer radionuclide therapies B. Brans, O. Linden, F. Giammarile, J. Tennvall and C. Punt	994
Current Perspective	
Evaluation of imatinib mesylate effects on glioblastoma aggressiveness with SPECT radiotracer ^{99m}Tc -(v)-DMSA N. Le Jeune, F. Dubois, V. Bin and N. Perek	1004
Reviews	
EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome F. Trautinger, R. Knobler, R. Willemze, K. Peris, R. Stadler, L. Laroche, M. D’Incan, A. Ranki, N. Pimpinelli, P. Ortiz-Romero, R. Dummer, T. Estrach and S. Whittaker	1014
RECIST revisited: A review of validation studies on tumour assessment P. Therasse, E.A. Eisenhauer and J. Verweij	1031
Short Communication	
SF-1 overexpression in childhood adrenocortical tumours M.A.D. Pianovski, L.R. Cavalli, B.C. Figueiredo, S.C.L. Santos, M. Doghman, R.C. Ribeiro, A.G. Oliveira, E. Michalkiewicz, G.A. Rodrigues, G. Zambetti, B.R. Haddad and E. Lalli	1040

Clinical Oncology

- Effects of third-generation aromatase inhibitors on bone 1044
E. McCloskey
- Defining the appropriate radiotherapy regimen for metastatic spinal cord compression in non-small cell lung cancer patients 1052
D. Rades, L.J.A. Stalpers, R. Schulte, T. Veninga, H. Basic, R. Engenhart-Cabilic, S.E. Schild and P.J. Hoskin
- Linking survival of HER2-positive breast carcinoma patients with surgical invasiveness 1057
E. Tagliabue, R. Agresti, P. Casalini, L. Mariani, M.L. Carcangiu, A. Balsari, U. Veronesi and S. Ménard
- Radical prostatectomy for locally advanced prostate cancer: Results of a feasibility study (EORTC 30001) 1062
H. Van Poppel, K. Vekemans, L. Da Pozzo, A. Bono, J. Kliment, R. Montironi, M. Debois and L. Collette
- Detection of colorectal cancer using MALDI-TOF serum protein profiling 1068
M.E. de Noo, B.J.A. Mertens, A. Özalp, M.R. Bladergroen, M.P.J. van der Werff, C.J.H. van de Velde, A.M. Deelder and R.A.E.M. Tollenaar
- Association between diabetes mellitus and adverse characteristics of breast cancer at presentation 1077
I. Wolf, S. Sadetzki, I. Gluck, B. Oberman, M. Ben-David, M.Z. Papa, R. Catane and B. Kaufman
- Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer 1083
N.A. Spry, L. Kristjanson, B. Hooton, L. Hayden, G. Neerhut, H. Gurney, T. Corica, E. Korbel, S. Weinstein and K. McCaul
- KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours 1093
M. Debiec-Rychter, R. Sciot, A. Le Cesne, M. Schlemmer, P. Hohenberger, A.T. van Oosterom, J.-Y. Blay, S. Leyvraz, M. Stul, P.G. Casali, J. Zalcberg, J. Verweij, M. Van Glabbeke, A. Hagemeyer and I. Judson, On behalf of the EORTC Soft Tissue and Bone Sarcoma Group, The Italian Sarcoma Group and the Australasian Gastrointestinal Trials Group
- Activated ERK1/2 and phosphorylated oestrogen receptor α are associated with improved breast cancer survival in women treated with tamoxifen 1104
J. Bergqvist, G. Elmberger, J. Ohd, B. Linderholm, J. Bjohle, H. Hellborg, H. Nordgren, A.-L. Borg, L. Skoog and J. Bergh

Paediatric Oncology

- International neuroblastoma pathology classification adds independent prognostic information beyond the prognostic contribution of age 1113
H. Sano, J. Bonadio, R.B. Gerbing, W.B. London, K.K. Matthay, J.N. Lukens and H. Shimada
- Analysis of patients with supratentorial primitive neuro-ectodermal tumours entered into the SIOP/UKCCSG PNET 3 study 1120
B.L. Pizer, C.L. Weston, K.J. Robinson, D.W. Ellison, J. Ironside, F. Saran, L.S. Lashford, D. Tait, H. Lucraft, D.A. Walker, C.C. Bailey and R.E. Taylor

Epidemiology and Cancer Prevention

- A specific RAD51 haplotype increases breast cancer risk in Jewish non-Ashkenazi high-risk women 1129
I. Gal, G. Kimmel, R. Gershoni-Baruch, M.Z. Papa, E. Dagan, R. Shamir and E. Friedman
- Updating long-term childhood cancer survival trend with period and mixed analysis: Good news from population-based estimates in Italy 1135
L. Zuccolo, E. Dama, M.M. Maule, G. Pastore, F. Merletti and C. Magnani
- BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives 1143
F. Laloo, J. Varley, A. Moran, D. Ellis, L. O'Dair, P. Pharoah, A. Antoniou, R. Hartley, A. Shenton, S. Seal, B. Bulman, A. Howell and D.G.R. Evans
- Adenocarcinoma of the oesophagus and gastric cardia: Male preponderance in association with obesity 1151
A.M. Ryan, S.P. Rowley, A.P. Fitzgerald, N. Ravi and J.V. Reynolds

Assessing health-related quality of life in palliative care: Comparing patient and physician assessments M.Aa. Petersen, H. Larsen, L. Pedersen, N. Sonne and M. Groenvold	1159
No increase in thyroid cancer among children and adolescents in Finland due to Chernobyl accident A. But, P. Kurttio, S. Heinävaara and A. Auvinen	1167
Experimental Oncology	
Malignant fibrous histiocytoma of bone: Analysis of genomic imbalances by comparative genomic hybridisation and C-MYC expression by immunohistochemistry M. Tarkkanen, M.L. Larramendy, T. Böhling, M. Serra, C.M. Hattinger, A. Kivioja, I. Elomaa, P. Picci and S. Knuutila	1172
Potential role of CCL27 and CCR10 expression in melanoma progression and immune escape O. Simonetti, G. Goteri, G. Lucarini, A. Filosa, T. Pieramici, C. Rubini, G. Biagini and A. Offidani	1181
A functional polymorphism in the promoter region of leptin gene increases susceptibility for non-small cell lung cancer R. Ribeiro, A.P. Araújo, A. Coelho, R. Catarino, D. Pinto, A. Araújo, C. Calçada, C. Lopes and R. Medeiros	1188
Calendar of Forthcoming Meetings	I

NUMBER 9

Special Issue on Cancer Stem Cells: Opportunities for Novel Diagnostics and Drug Discovery
Guest Editors: W. Nicol Keith

Editorial Comment

Cancer stem cells: Opportunities for novel diagnostics and drug discovery W.N. Keith	1195
Telomeres and telomerase in cancer stem cells Z. Ju and K.L. Rudolph	1197
Stem cell properties and epithelial malignancies I.C. Mackenzie	1204
Prostate cancer stem cells A.T. Collins and N.J. Maitland	1213
Breast cancer stem cells: An overview D. Ponti, N. Zaffaroni, C. Capelli and M.G. Daidone	1219
Mammary stem and progenitor cells: Tumour precursors? A. Páguirigan, D.J. Beebe, B. Liu and C. Alexander	1225
Brain cancer stem-like cells T. Kondo	1237
Therapeutic potential of adult stem cells N. Serakinci and W.N. Keith	1243
Stem cell plasticity and tumour formation M.R. Alison, M.J. Lovell, N.C. Direkze, N.A. Wright and R. Poulson	1247
Mechanisms of self-renewal in human embryonic stem cells R. Stewart, M. Stojkovic and M. Lako	1257
Profiling cancer stem cells using protein array technology S. Nishizuka	1273
Epidermal stem cells and cancer stem cells: Insights into cancer and potential therapeutic strategies L.E. Finlan and T.R. Hupp	1283

Strategies to eliminate cancer stem cells: Clinical implications C.A. Huff, W.H. Matsui, B.D. Smith and R.J. Jones	1293
Neural stem cells as novel cancer therapeutic vehicles S. Yip, R. Sabetrasekh, R.L. Sidman and E.Y. Snyder	1298
Delivering cancer stem cell therapies – A role for nanomedicines? A.G. Schätzlein	1309

NUMBER 10

In this issue	xii
News	1317
Position Papers	
Update in methodology and conduct of cancer clinical trials P. Therasse, E.A. Eisenhauer and M. Buyse	1322
EUSOMA accreditation of breast units R.W. Blamey and L. Cataliotti	1331
Current Perspective	
Development of novel cancer chemopreventive agents in Europe – Neglected Cinderella or rising phoenix? ESF Workshop on Cancer Chemoprevention, DKFZ, Heidelberg, September 18–20, 2005 C. Gerhauser, H. Bartsch, J. Crowell, S. De Flora, M. D'Incalci, C. Dittrich, N. Frank, E. Mihich, C. Steffen, G. Tortora and A. Gescher	1338
Reviews	
Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials L. Collette, T. Burzykowski and F.H. Schröder	1344
Multiple targeted tyrosine kinase inhibition in the clinic: All for one or one for all? M.J.A. de Jonge and J. Verweij	1351
Short Communication	
Low somatic K-ras mutation frequency in colorectal cancer diagnosed under the age of 45 years K. Alsop, L. Mead, L.D. Smith, S.G. Royce, A.A. Tesoriero, J.P. Young, A. Haydon, G. Grubb, G.G. Giles, M.A. Jenkins, J.L. Hopper and M.C. Southey	1357
Clinical Oncology	
Using the continual reassessment method: Lessons Learned from an EORTC phase I dose finding study X. Paoletti, B. Baron, P. Schöffski, P. Fumoleau, D. Lacombe, S. Marreaud and R. Sylvester	1362
Tumour response to preoperative anthracycline-based chemotherapy in operable breast cancer: the predictive role of p53 expression J.S.D. Mieog, J.A. van der Hage, M.J. van de Vijver and C.J.H. van de Velde, Cooperating Investigators of the EORTC	1369
High frequency of BRCA1 5382insC mutation in Russian breast cancer patients A.P. Sokolenko, N.V. Mitiushkina, K.G. Buslov, E.M. Bit-Sava, A.G. Iyevleva, E.V. Chekmariova, E. Sh Kuligina, Y.M. Ulibina, M.E. Rozanov, E.N. Suspitsin, D.E. Matsko, O.L. Chagunava, D. Yu Trofimov, P. Devilee, C. Cornelisse, A.V. Togo, V.F. Semiglazov and E.N. Imyanitov	1380
Screening younger women with a family history of breast cancer – does early detection improve outcome? A. Maurice, D.G.R. Evans, A. Shenton, L. Ashcroft, A. Baildam, L. Barr, G. Byrne, N. Bundred, C. Boggis, M. Wilson, S.W. Duffy and A. Howell	1385

Quality assurance of thoracic radiotherapy in EORTC 08941: A randomised trial of surgery versus thoracic radiotherapy in patients with stage IIIA non-small-cell lung cancer (NSCLC) after response to induction chemotherapy G.W.P.M. Kramer, C.L. Legrand, P. van Schil, L. Uitterhoeve, E.F. Smit, F. Schramel, B. Biesma, V. Tjan-Heijnen, N. van Zandwijk, T. Splinter, G. Giaccone and J.P. van Meerbeeck, on behalf of EORTC-Lung Cancer Group	1391
Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European organization for research and treatment of cancer (EORTC 08984) B. Biesma, C. Manegold, H.J.M. Smit, L. Willems, C. Legrand, A. Passiukov, J.P. van Meerbeeck and G. Giaccone, for the EORTC Lung Cancer Group	1399
Quality of life and persisting symptoms after oesophageal cancer surgery P. Viklund, Y. Wengström, I. Rouvelas, M. Lindblad and J. Lagergren	1407
Paediatric Oncology	
Imminent ovarian failure in childhood cancer survivors G.M. Lantinga, A.H.M. Simons, W.A. Kamps and A. Postma	1415
Predictors of clinic satisfaction among adult survivors of childhood cancer K. Absolom, D. Greenfield, R. Ross, B. Horne, H. Davies, A. Glaser, A. Simpson, H. Waite and C. Eiser	1421
Epidemiology and Cancer Prevention	
Segregation analysis of urothelial cell carcinoma K.K.H. Aben, L. Baglietto, A. Baffoe-Bonnie, J.-W.W. Coebergh, J.E. Bailey-Wilson, B. Trink, A.L.M. Verbeek, M.P. Schoenberg, J.A. Witjes and L.A. Kiemeny	1428
Survival from rectal and anal cancers in England and Wales, 1986–2001 M. Jeffreys, B. Rachet, S. McDowell, A.G. Habib, C. Lepage and M.P. Coleman	1434
Sun exposure and sunburn among Swedish toddlers R. Bränström, S. Kristjansson, H. Dal and Y. Rodvall	1441
Hair dye use is not associated with risk for bladder cancer: Evidence from a case-control study in Spain M. Kogevinas, F. Fernandez, M. Garcia-Closas, A. Tardon, R. Garcia-Closas, C. Serra, A. Carrato, G. Castano-Vinyals, M. Yeager, S.J. Chanock, J. Lloreta, N. Rothman, F.X. Real, M. Dosemeci, N. Malats and D. Silverman	1448
Experimental Oncology	
RhoA and RhoC proteins promote both cell proliferation and cell invasion of human oesophageal squamous cell carcinoma cell lines in vitro and in vivo A. Faried, L.S. Faried, H. Kimura, M. Nakajima, M. Sohda, T. Miyazaki, H. Kato, N. Usman and H. Kuwano	1455
Ets2 binding site single nucleotide polymorphism at the hTERT gene promoter – effect on telomerase expression and telomere length maintenance in non-small cell lung cancer C.-P. Hsu, N.-Y. Hsu, L.-W. Lee and J.-L. Ko	1466
Establishment and characterization of xenografts and cancer cell cultures derived from BRCA1 –/– epithelial ovarian cancers S. Indraccolo, V. Tisato, S. Agata, L. Moserle, S. Ferrari, M. Callegaro, L. Persano, M.D. Palma, M.C. Scaini, G. Esposito, A. Fassina, O. Nicoletto, M. Plebani, L. Chieco-Bianchi, A. Amadori, E. D’Andrea and M. Montagna	1475
Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma F. Grosso, P. Dileo, R. Sanfilippo, S. Stacchiotti, R. Bertulli, C. Piovesan, J. Jimeno, M. D’Incalci, A. Gescher and P.G. Casali	1484
PI3-K/Akt-mediated anoikis resistance of human osteosarcoma cells requires Src activation C.M. Díaz-Montero, J.N. Wygant and B.W. McIntyre	1491
Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysis R. Merola, M. Mottolese, G. Orlandi, E. Vico, F. Cognetti, I. Sperduti, A. Fabi, G. Vitelli and A.M. Cianciulli	1501
Calendar of Forthcoming Meetings	

160 Years of Multiple Myeloma: Progress and Challenges**Guest Editors: M. Engelhardt, R. Mertelsmann***Editorial Comment*

- 160 years of multiple myeloma: Progress and challenges 1507
M. Engelhardt and R. Mertelsmann

New Developments in Understanding the Biology and Genetics of Multiple Myeloma

- Conventional diagnostics in multiple myeloma 1510
J.F.S. Miguel, N.C. Gutiérrez, G. Mateo and A. Orfao
- Cytogenetics and molecular cytogenetics in multiple myeloma 1520
P. Liebis and H. Döhner
- Genetics and molecular profiling of multiple myeloma: Novel tools for clinical management? 1530
P. Tassone, P. Tagliaferri, M. Rossi, M. Gaspari, R. Terracciano and S. Venuta
- The role of anatomic and functional staging in myeloma: Description of Durie/Salmon plus staging system 1539
B.G.M. Durie
- Bone markers in multiple myeloma 1544
U. Heider, C. Fleissner, I. Zavrski, M. Kaiser, M. Hecht, C. Jakob and O. Sezer
- Myeloma bone disease and treatment options 1554
H.S. Yeh and J.R. Berenson
- The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: Interplay of growth factors, their receptors and stromal interactions 1564
C.S. Mitsiades, N.S. Mitsiades, N.C. Munshi, P.G. Richardson and K.C. Anderson
- Signalling and survival pathways in multiple myeloma 1574
K. Bommert, R.C. Bargou and T. Stühmer
- Angiogenesis in multiple myeloma 1581
C. Jakob, J. Sterz, I. Zavrski, U. Heider, L. Kleeberg, C. Fleissner, M. Kaiser and O. Sezer

Current and Developing Therapies in Multiple Myeloma

- State of the art therapy in multiple myeloma and future perspectives 1591
U. Denz, P.S. Haas, R. Wäsch, H. Einsele and M. Engelhardt
- Allogeneic haematopoietic cell transplantation for multiple myeloma: Reducing transplant-related mortality while harnessing the graft-versus-myeloma effect 1601
R. Zeiser and J. Finke
- Thalidomide and lenalidomide in the treatment of multiple myeloma 1612
S. Kumar and S.V. Rajkumar
- Proteasome inhibition in multiple myeloma 1623
M. Kropff, G. Bisping, D. Wenning, W.E. Berdel and J. Kienast
- Multiple myeloma: Monoclonal antibodies-based immunotherapeutic strategies and targeted radiotherapy 1640
M. Chatterjee, T. Chakraborty and P. Tassone
- Active immunotherapy of multiple myeloma 1653
L. Houet and H. Veelken

Epidemiology and Varia on Multiple Myeloma

- Familial risks and temporal incidence trends of multiple myeloma 1661
A. Altieri, B. Chen, J.L. Bermejo, F. Castro and K. Hemminki

Epidemiology and outcomes research for MGUS, myeloma and amyloidosis B. Sirohi and R. Powles	1671
An update: Health economics of managing multiple myeloma K. Moeremans and L. Annemans	1684

NUMBER 12

News	1693
Short Communication	
(CA) _n Microsatellite polymorphism of ERBB-1 in breast cancer M. Welnicka-Jaśkiewicz, A. Żaczek, B. Brandt, K.P. Bielański, J. Jaśkiewicz, K. Konopa and J. Jassem	1698
Position Papers	
Role of complementary and alternative medicine in the care of patients with breast cancer: Report of the European Society of Mastology (EUSOMA) Workshop, Florence, Italy, December 2004 M. Baum, E. Ernst, S. Lejeune and M. Horneber	1702
The role of complementary and alternative medicine in the management of early breast cancer: Recommendations of the European Society of Mastology (EUSOMA) M. Baum, B.R. Cassileth, R. Daniel, E. Ernst, J. Filshie, G.A. Nagel, M. Horneber, M. Kohn, S. Lejeune, J. Maher, R. Terje and W.B. Smith	1711
Current Perspectives	
Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: What we know and what we still need to learn M.J. Piccart-Gebhart	1715
Clinical molecular imaging with positron emission tomography A. Saleem, N. Charnley and P. Price	1720
Reviews	
Molecular prognostic markers in resectable colorectal liver metastases: A systematic review C.P. Neal, G. Garcea, H. Doucas, M.M. Manson, C.D. Sutton, A.R. Dennison and D.P. Berry	1728
Why don't cancer patients enter clinical trials? A review P. Castel, S. Négrier and J.-P. Boissel, on behalf of the Plateforme d'Aide à la Recherche Clinique en Cancérologie de la région Rhône-Alpes	1744
Clinical Oncology	
Clinical factors associated with fatigue in haematologic cancer patients receiving stem-cell transplantation J.M. Prieto, J. Blanch, J. Atala, E. Carreras, M. Rovira, E. Cirera and C. Gastó	1749
Thyroid metastases from colorectal cancer: The Institut Gustave Roussy experience A. Lièvre, S. Leboulleux, V. Boige, J.-P. Travagli, C. Dromain, D. Elias, M. Ducreux and D. Malka	1756
Information provision for patients by breast cancer teams about the side-effects of hormone treatments R. McGurk, L. Fallowfield and Z. Winters	1760
Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours M.J.A. de Jonge, H. Dumez, J. Verweij, S. Yarkoni, D. Snyder, D. Lacombe, S. Maréchal, T. Yamaguchi, C.J.A. Punt and A. van Oosterom, on behalf of the EORTC New Drug Development Group (NDDG)	1768
Activity of thalidomide in patients with platinum-refractory germ-cell tumours O. Rick, T. Braun, W. Siegert and J. Beyer	1775

CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: A randomised trial (GABG trial IV-A-93) G. von Minckwitz, E. Graf, M. Geberth, W. Eiermann, W. Jonat, B. Conrad, K. Brunnert, B. Gerber, S. Vescia, J. Wollert and M. Kaufmann	1780
A phase I clinical and pharmacokinetic study of paclitaxel and docetaxel given in combination in patients with solid tumours M.A. Izquierdo, M. García, J.L. Pontón, M. Martínez, V. Valentí, M. Navarro, M. Gil, F. Cardenal, R. Mesía, X. Pérez, R. Salazar and J.R. Germà-Lluch	1789
Gemcitabine and split-dose paclitaxel or docetaxel in metastatic breast cancer: A randomised phase II study K.S. Khoo, S.H.M. Zaidi, V. Srimuninnimit, S. Song, R. Nair, C.A. Ngelangel, A. Bustam, W.H.H. Reece and M. Lehnert	1797
Paediatric Oncology	
Prognostic factors for progression of childhood optic pathway glioma: A systematic review E. Opocher, L.C.M. Kremer, L. Da Dalt, M.D. van de Wetering, E. Viscardi, H.N. Caron and G. Perilongo	1807
Establishing content validity of the oral assessment guide in children and young people F. Gibson, J. Cargill, J. Allison, J. Begent, S. Cole, J. Stone and V. Lucas	1817
Multilocus loss of heterozygosity allelotypes identify a genetic pathway associated with progression from low to high stage disease in neuroblastoma S.A. Chughtai, T. Genus, P. Ramani, S. Dyer, J.E. Powell, D. McMullan, V. Davison and C.M. McConville, On behalf of the UK Children's Cancer Study Group	1826
Epidemiology and Cancer Prevention	
Past chlamydial infection is not associated with primary fallopian tube carcinoma A. Riska, P. Finne, H. Alfthan, T. Anttila, J. Jalkanen, T. Sorvari, U.H. Stenman, J. Paavonen and A. Leminen	1835
Translation and validation of the EORTC QLQ-C30 for use among Turkish and Moroccan ethnic minority cancer patients in the Netherlands R. Hoopman, M.J. Muller, C.B. Terwee and N.K. Aaronson	1839
Restrictions in quality of life in colorectal cancer patients over three years after diagnosis: A population based study V. Arndt, H. Merx, C. Stegmaier, H. Ziegler and H. Brenner	1848
Prostate cancer specific mortality in the Florence screening pilot study cohort 1992–1993 S. Ciatto, G. Gervasi, G. Gorini, C. Lombardi, M. Zappa and E. Crocetti	1858
Meta-analysis of the prognostic significance of perinodal spread in head and neck squamous cell carcinomas (HNSCC) patients A.A. Dünne, H.H. Müller, D.W. Eisele, K. Keßel, R. Moll and J.A. Werner	1863
Experimental Oncology	
Re-analysis of the Xq27–Xq28 region suggests a weak association of an X-linked gene with sporadic testicular germ cell tumour without cryptorchidism M.F. Lutke Holzik, H.J. Hoekstra, R.H. Sijmons, D.J.A. Sonneveld, G. van der Steege, D.Th. Sleijfer and I.M. Nolte	1869
Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus I. Duran, L.L. Siu, A.M. Oza, T.-B. Chung, J. Sturgeon, C.A. Townsley, G.R. Pond, L. Seymour and M. Niroumand	1875
TRF2 inhibition triggers apoptosis and reduces tumourigenicity of human melanoma cells A. Biroccio, A. Rizzo, R. Elli, C.-E. Koering, A. Belleville, B. Benassi, C. Leonetti, M.F.G. Stevens, M. D'Incalci, G. Zupi and E. Gilson	1881
Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer M.N. Holten-Andersen, H.J. Nielsen, S. Sørensen, V. Jensen, N. Brünnert and I.J. Christensen	1889
Prediction of peritoneal metastasis in advanced gastric cancer by gene expression profiling of the primary site M. Motoori, I. Takemasa, Y. Doki, S. Saito, H. Miyata, S. Takiguchi, Y. Fujiwara, T. Yasuda, M. Yano, Y. Kurokawa, T. Komori, M. Yamasaki, N. Ueno, S. Oba, S. Ishii, M. Monden and K. Kato	1897

Clinical significance of Vascular Endothelial Growth Factor-A expression in Ewing's sarcoma M. Kreuter, M. Paulussen, J. Boeckeler, J. Gerss, H. Buerger, C. Liebscher, T. Kessler, H. Jurgens, W.E. Berdel and R.M. Mesters	1904
---	------

<i>Calendar of Forthcoming Meetings</i>	I
---	---

NUMBER 13

Cancer in Children and Adolescents in Europe

Guest Editors: E. Steliarova-Foucher, J.W. Coebergh, P. Kaatsch, K. Pritchard-Jones, C. Stiller

<i>Foreword</i> G. Henze	1913
Quality, comparability and methods of analysis of data on childhood cancer in Europe (1978–1997): Report from the Automated Childhood Cancer Information System project E. Steliarova-Foucher, P. Kaatsch, B. Lacour, V. Pompe-Kirn, S. Eser, A. Miranda, A. Danzon, A. Ratiu and D.M. Parkin	1915
Geographical patterns of childhood cancer incidence in Europe, 1988–1997. Report from the Automated Childhood Cancer Information System project C.A. Stiller, R. Marcos-Gragera, E. Ardanaz, F. Pannelli, E.A. Marqués, A.C. Martinez and E. Steliarova-Foucher	1952
Time trends of cancer incidence in European children (1978–1997): Report from the Automated Childhood Cancer Information System project P. Kaatsch, E. Steliarova-Foucher, E. Crocetti, C. Magnani, C. Spix and P. Zambon	1961
Geographical comparison of cancer survival in European children (1988–1997): Report from the Automated Childhood Cancer Information System project R. Sankila, M.C.M. Jiménez, D. Miljus, K. Pritchard-Jones, E. Steliarova-Foucher and C. Stiller	1972
Trends in survival after childhood cancer in Europe, 1978–1997: Report from the Automated Childhood Cancer Information System project (ACCIS) C. Magnani, G. Pastore, J.W. Coebergh, S. Viscomi, C. Spix and E. Steliarova-Foucher	1981
Cancer incidence and survival in European adolescents (1978–1997). Report from the Automated Childhood Cancer Information System project C.A. Stiller, E. Desandes, S.E. Danon, I. Izarzugaza, A. Ratiu, Z. Vassileva-Valerianova and E. Steliarova-Foucher	2006
Leukaemia incidence and survival in children and adolescents in Europe during 1978–1997. Report from the Automated Childhood Cancer Information System project J.W.W. Coebergh, A.M.J. Reedijk, E. de Vries, C. Martos, Z. Jakab, E. Steliarova-Foucher and W.A. Kamps	2019
Hodgkin's disease incidence and survival in European children and adolescents (1978–1997): Report from the Automated Cancer Information System project J. Clavel, E. Steliarova-Foucher, C. Berger, S. Danon and Z. Valerianova	2037
Non-Hodgkin's lymphoma incidence and survival in European children and adolescents (1978–1997): Report from the Automated Childhood Cancer Information System project M.I. Izarzugaza, E. Steliarova-Foucher, M.C. Martos and S. Zivkovic	2050
Childhood central nervous system tumours – incidence and survival in Europe (1978–1997): Report from Automated Childhood Cancer Information System project R. Peris-Bonet, C. Martínez-García, B. Lacour, S. Petrovich, B. Giner-Ripoll, A. Navajas and E. Steliarova-Foucher	2064
Neuroblastoma incidence and survival in European children (1978–1997): Report from the Automated Childhood Cancer Information System project C. Spix, G. Pastore, R. Sankila, C.A. Stiller and E. Steliarova-Foucher	2081

Retinoblastoma incidence and survival in European children (1978–1997). Report from the Automated Childhood Cancer Information System project <i>A. MacCarthy, G.J. Draper, E. Steliarova-Foucher and J.E. Kingston</i>	2092
Malignant renal tumours incidence and survival in European children (1978–1997): Report from the Automated Childhood Cancer Information System project <i>G. Pastore, A. Znaor, F. Spreafico, N. Graf, K. Pritchard-Jones and E. Steliarova-Foucher</i>	2103
Liver cancer in European children: Incidence and survival, 1978–1997. Report from the Automated Childhood Cancer Information System project <i>C.A. Stiller, J. Pritchard and E. Steliarova-Foucher</i>	2115
Bone tumours in European children and adolescents, 1978–1997. Report from the Automated Childhood Cancer Information System project <i>C.A. Stiller, S.S. Bielack, G. Jundt and E. Steliarova-Foucher</i>	2124
Childhood soft tissue sarcomas incidence and survival in European children (1978–1997): Report from the Automated Childhood Cancer Information System project <i>G. Pastore, R. Peris-Bonet, M. Carli, C. Martínez-García, J.S. de Toledo and E. Steliarova-Foucher</i>	2136
Thyroid cancer incidence and survival among European children and adolescents (1978–1997): Report from the Automated Childhood Cancer Information System project <i>E. Steliarova-Foucher, C.A. Stiller, E. Pukkala, B. Lacour, I. Plesko and D.M. Parkin</i>	2150
Skin cancer incidence and survival in European children and adolescents (1978–1997). Report from the Automated Childhood Cancer Information System project <i>E. de Vries, E. Steliarova-Foucher, A. Spatz, E. Ardanaz, A.M.M. Eggermont and J.W.W. Coebergh</i>	2170
Cancer in children and adolescents in Europe: Developments over 20 years and future challenges <i>K. Pritchard-Jones, P. Kaatsch, E. Steliarova-Foucher, C.A. Stiller and J.W.W. Coebergh</i>	2183

NUMBER 14

News	2191
Short Communication	
A randomised phase III study comparing high-dose chemotherapy to conventionally dosed chemotherapy for stage III ovarian cancer: The Finnish Ovarian Cancer (FINOVA) study <i>S. Grénman, T. Wiklund, J. Jalkanen, T. Kuoppala, J. Mäenpää, A. Kuronen, A. Leminen, U. Puistola, P. Vuolo-Merilä, T. Salmi, M. Vuento, M. Yliskoski, M. Itälä, H. Helenius, H. Joensuu and P. Lehtovirta</i>	2196
Position Papers	
Background to Eusoma guidelines and statements <i>M. Greco and L. Marotti, on behalf of Eusoma Executive Committee</i>	2200
The management of lobular carcinoma in situ (LCIS). Is LCIS the same as ductal carcinoma in situ (DCIS)? <i>S.R. Lakhani, W. Audretsch, A.-M. Cleton-Jensen, B. Cutuli, I. Ellis, V. Eusebi, M. Greco, R.S. Houslton, C.K. Kuhl, J. Kurtz, J. Palacios, H. Peterse, F. Rochard and E. Rutgers, on behalf of EUSOMA</i>	2205
Current Perspective	
Towards a pan-European consensus on the treatment of patients with colorectal liver metastases <i>E. Van Cutsem, B. Nordlinger, R. Adam, C.-H. Köhne, C. Pozzo, G. Poston, M. Ychou and P. Rougier, on behalf of European Colorectal Metastases Treatment Group</i>	2212

Reviews

- Does sunlight prevent cancer? A systematic review 2222
H.J. van der Rhee, E. de Vries and J.W.W. Coebergh

- The clinical trail of TRAIL 2233
E.W. Duiker, C.H. Mom, S. de Jong, P.H.B. Willemse, J.A. Gietema, A.G.J. van der Zee and E.G.E. de Vries

- Marine pharmacology in 2003–2004: Anti-tumour and cytotoxic compounds 2241
A.M.S. Mayer and K.R. Gustafson

Clinical Oncology

- Intentional and non-intentional non-adherence to medication amongst breast cancer patients 2271
L. Atkins and L. Fallowfield

- Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG) 2277
M. Van Glabbeke, J. Verweij, P.G. Casali, J. Simes, A. Le Cesne, P. Reichardt, R. Issels, I.R. Judson, A.T. van Oosterom and J.-Y. Blay

- Pathological response to preoperative concurrent chemo-radiotherapy for breast cancer: Results of a phase II study 2286
M.A. Bollet, B. Sigal-Zafrani, L. Gambotti, J.-M. Extra, M. Meunier, C. Nos, R. Dendale, F. Campana, Y.M. Kirova, V. Diéras and A. Fourquet, for the Institut Curie Breast Cancer Study Group

- Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: Clinical considerations 2296
G. Ferrandina, F. Legge, V. Salutati, A. Paglia, A. Testa and G. Scambia

- Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx®) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas 2303
O.S. Nielsen, P. Reichardt, T.B. Christensen, D. Pink, S. Daugaard, C. Hermans, S. Marreud, M. van Glabbeke, J. Blay and I. Judson

- Patient-reported assessment of quality care at end of life: Development and validation of Quality Care Questionnaire–End of Life (QCQ–EOL) 2310
Y.H. Yun, S.-H. Kim, K.-M. Lee, S.M. Park, C.G. Lee, Y.S. Choi, W.S. Lee, S.-Y. Kim and D.S. Heo

- Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: Phase I clinical trial of three dosing schedules in patients with solid malignancies 2318
R.A. Sharma, W.P. Steward, C.A. Daines, R.D. Knight, K.J. O'Byrne and A.G. Dalglish

Paediatric Oncology

- The tumour suppressor hSNF5/INI1 controls the differentiation potential of malignant rhabdoid cells 2326
P. Albanese, M.-F. Belin and O. Delattre

- Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours 2335
S. Baruchel, M. Diezi, D. Hargrave, D. Stempak, J. Gammon, A. Moghrabi, M.J. Coppes, C.V. Fernandez and E. Bouffet

Epidemiology and Cancer Prevention

- Familial risk for histology-specific bone cancers: An updated study in Sweden 2343
J. Ji and K. Hemminki

- Neuroblastoma in Hungary 2350
T.A. Nyári, P. Kajtár and L. Parker, The Hungarian Paediatric Oncology Group

- Depleted uranium and cancer in Danish Balkan veterans deployed 1992–2001 2355
H.H. Storm, H.O. Jørgensen, A.M.T. Kejs and G. Engholm

Chewing gum and risk of oesophageal adenocarcinoma: A new hypothesis tested in a population-based study <i>J. Lagergren, C. Jansson and P. Viklund</i>	2359
Incidence of and survival from Wilms' tumour in adults in Europe: Data from the EURO CARE study <i>E. Mitry, L. Ciccolallo, M.P. Coleman, G. Gatta and K. Pritchard-Jones, EURO CARE Working Group</i>	2363
Experimental Oncology	
Mutational analysis of the hCDC4 gene in gastric carcinomas <i>J.W. Lee, Y.H. Sung, H.J. Kim, W.S. Park, S.W. Nam, S.H. Kim, J.Y. Lee, N.J. Yoo and S.H. Lee</i>	2369
Overexpression of poly(ADP-ribose) polymerase-1 (PARP-1) in the early stage of colorectal carcinogenesis <i>K. Nosh, H. Yamamoto, M. Mikami, H. Taniguchi, T. Takahashi, Y. Adachi, A. Imamura, K. Imai and Y. Shinomura</i>	2374
Role of prostaglandin E2 in the invasiveness, growth and protection of cancer cells in malignant pleuritis <i>E. Pace, L. Siena, M. Ferraro, M. Profita, P. Mondello, G. Chiappara, A.M. Montalbano, A. Giarratano, G. Bonsignore and M. Gjomarkaj</i>	2382
Immunocytochemical localisation of plasma membrane GHRH receptors in human tumours using a novel anti-peptide antibody <i>S. Schulz, C. Röcken and S. Schulz</i>	2390
Decreased expression of the adhesion molecule desmoglein-2 is associated with diffuse-type gastric carcinoma <i>M. Yashiro, N. Nishioka and K. Hirakawa</i>	2397
Diffusivity and distribution of vinblastine in three-dimensional tumour tissue: Experimental and mathematical modelling <i>S. Modok, P. Hyde, H.R. Mellor, T. Roose and R. Callaghan</i>	2404
Calendar of Forthcoming Meetings	I

NUMBER 15

News	2415
Short Communications	
Expression of transcription factor Yin Yang 1 in human osteosarcomas <i>F. de Nigris, C. Botti, A. de Chiara, R. Rossiello, G. Apice, F. Fazioli, C. Fiorito, V. Sica and C. Napoli</i>	2420
A genomic explanation connecting "Mediterranean diet", olive oil and cancer: Oleic acid, the main monounsaturated Fatty acid of olive oil, induces formation of inhibitory "PEA3 transcription factor-PEA3 DNA binding site" complexes at the Her-2/neu (erbB-2) oncogene promoter in breast, ovarian and stomach cancer cells <i>J.A. Menendez, A. Papadimitropoulou, L. Vellon and R. Lupu</i>	2425
Position Papers	
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours <i>M.S. Aapro, D.A. Cameron, R. Pettengell, J. Bohlius, J. Crawford, M. Ellis, N. Kearney, G.H. Lyman, V.C. Tjan-Heijnen, J. Walewski, D.C. Weber and C. Zielinski, European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party</i>	2433
Patients and health professionals working together to improve clinical research: Where are we going? <i>H. Thornton</i>	2454
Current Perspective	
The multidisciplinary meeting: An indispensable aid to communication between different specialities <i>T. Ruhstaller, H. Roe, B. Thürlimann and J.J. Nicoll</i>	2459

Reviews

- Are men with low selenium levels at increased risk of prostate cancer? 2463
M. Brinkman, R.C. Reulen, E. Kellen, F. Buntinx and M.P. Zeegers
- To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: Pilot study using dynamic contrast-enhanced Doppler ultrasound 2472
M. Lamuraglia, B. Escudier, L. Chami, B. Schwartz, J. Leclère, A. Roche and N. Lassau
- Breast cancer: Multidisciplinary care and clinical outcomes 2480
N. Houssami and R. Sainsbury

Clinical Oncology

- Numerous high-risk epithelial lesions in familial breast cancer 2492
N. Hoogerbrugge, P. Bult, J.J. Bonenkamp, M.J.L. Ligtenberg, L.A. Kiemeny, J.A. de Hullu, C. Boetes, M.F. Niermeijer and H.G. Brunner
- 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment 2499
M.C.M. Kouwenhoven, J.M. Kros, P.J. French, E.M. Biemond-ter Stege, W.J. Graveland, M.J.B. Taphoorn, A.A. Brandes and M.J. van den Bent
- Failure of dietetic referral in patients with gastrointestinal cancer and weight loss 2504
C. Baldwin, C. McGough, A.R. Norman, G.S. Frost, D.C. Cunningham and H.J.N. Andreyev
- Prognostic significance of symptoms of hospitalised advanced cancer patients 2510
S.C. Teunissen, A. de Graeff, H.C. de Haes and E.E. Voest
- The role of child abuse and age in vulnerability to emotional problems after surgery for breast cancer 2517
P. Salmon, J. Hill, R. Krespi, L. Clark, J. Fisher and C. Holcombe
- Hepatitis B- and C-related hepatocellular carcinomas yield different clinical features and prognosis 2524
C.-H. Chen, G.-T. Huang, P.-M. Yang, P.-J. Chen, M.-Y. Lai, D.-S. Chen, J.-D. Wang and J.-C. Sheu
- A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients 2530
R. Oberneder, D. Weckermann, B. Ebner, C. Quadt, P. Kirchinger, T. Raum, M. Locher, N. Prang, P.A. Baeuerle and E. Leo
- Alterations in the p53 pathway and prognosis in advanced ovarian cancer: A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865) 2539
J.A. Green, E.M.J.J. Berns, C. Coens, I. van Luijk, J. Thompson-Hehir, P. van Diest, R.H.M. Verheijen, M. van de Vijver, P. van Dam, G.G. Kenter, W. Tjalma, P.C. Ewing, I. Teodorovic, I. Vergote and M.E.L. van der Burg, On behalf of the EORTC Gynaecological Cancer Group

Paediatric Oncology

- Clinical heart failure during pregnancy and delivery in a cohort of female childhood cancer survivors treated with anthracyclines 2549
E.C. van Dalen, H.J.H. van der Pal, C. van den Bos, W.E.M. Kok, H.N. Caron and L.C.M. Kremer
- Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms' tumour: Results of a randomised trial (UKW3) by the UK Children's Cancer Study Group 2554
C. Mitchell, K. Pritchard-Jones, R. Shannon, C. Hutton, S. Stevens, D. Machin, J. Imeson, A. Kelsey, G.M. Vujanic, P. Gornall, J. Walker, R. Taylor, P. Sartori, J. Hale, G. Levitt, B. Messahel, H. Middleton, R. Grundy and J. Pritchard, For the United Kingdom Cancer Study Group
- Long term morbidity and health related quality of life after multi-system Langerhans cell histiocytosis 2563
V.R. Nanduri, J. Pritchard, G. Levitt and A.W. Glaser

Epidemiology and Cancer Prevention

- Influence of familial cancer history on lymphoid neoplasms risk validated in the large European case-control study epilymph 2570
R. Casey, P. Brennan, N. Becker, P. Boffetta, P. Cocco, E. Domingo-Domenech, L. Foretova, A. Nieters, S. de Sanjosé, A. Staines, M. Vornanen and M. Maynadié

Mortality from cancer among ethnic German immigrants from the Former Soviet Union, in Germany C. Kyobutungi, U. Ronellenfitsch, O. Razum and H. Becher	2577
Low levels of breast cancer risk awareness in young women: An international survey V. Peacey, A. Steptoe, S. Davídsdóttir, A. Baban and J. Wardle	2585
Physical activity, obesity, and risk of colon and rectal cancer in a cohort of Swedish men S.C. Larsson, J. Rutegård, L. Bergkvist and A. Wolk	2590
Variation in relative survival of thyroid cancers in Europe: Results from the analysis on 21 countries over the period 1983–1994 (EUROCARE-3 study) M. Colonna, E. Grande and J.G. Jónasson, EUROCARE Working Group	2598
Experimental Oncology	
5-Aminosalicylic acid enhances anchorage-independent colorectal cancer cell death D. Fina, L. Franchi, R. Caruso, I. Peluso, G.C. Naccari, S. Bellinva, R. Testi, F. Pallone and G. Monteleone	2609
Molecular detection of EGFRvIII-positive cells in the peripheral blood of breast cancer patients H.A.C. Silva, E. Abraül, D. Raimundo, M.F. Dias, C. Marques, C. Guerra, C.F. de Oliveira and F.J. Regateiro	2617
Modulation of cell growth and cisplatin sensitivity by membrane γ -glutamyltransferase in melanoma cells M. Franzini, A. Corti, E. Lorenzini, A. Paolicchi, A. Pompella, M. De Cesare, P. Perego, L. Gatti, R. Leone, P. Apostoli and F. Zunino	2623
Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas S. Ullisse, E. Baldini, M. Toller, E. Marchioni, L. Giacomelli, E. De Antoni, E. Ferretti, A. Marzullo, F.M. Graziano, P. Trimboli, L. Biordi, F. Curcio, A. Gulino, F.S. Ambesi-Impimbato and M. D'Armiento	2631
Overexpression of a member of the pentraxin family (PTX3) in human soft tissue liposarcoma F. Willeke, A. Assad, P. Findeisen, E. Schromm, R. Grobholz, B. von Gerstenbergk, A. Mantovani, S. Peri, H.H. Friess, S. Post, M. von Knebel Doeberitz and M.H.M. Schwarzbach	2639
Identification of a common polymorphism in the TopBP1 gene associated with hereditary susceptibility to breast and ovarian cancer S.-M. Karppinen, H. Erkkö, K. Reini, H. Pospiech, K. Heikkinen, K. Rapakko, J.E. Syväoja and R. Winqvist	2647
Increasing oxidative damage and loss of mismatch repair enzymes during breast carcinogenesis P. Karihtala, R. Winqvist, J.E. Syväoja, V.L. Kinnula and Y. Soini	2653
Correspondence	
Trastuzumab (Herceptin®) in patients with HER-2-overexpressing metastatic or locally advanced transitional cell carcinoma of the bladder: report on 7 patients M. Salzberg, M. Borner, J.-A. Bauer, R. Morant, D. Rauch and C. Rochlitz	2660
Calendar of Forthcoming Meetings	I
NUMBER 16	
News	2663
Editorial Comment	
JAK/STAT signalling pathway in colorectal cancer: A new biological target with therapeutic implications J.-P. Spano, G. Milano, C. Rixe and R. Fagard	2668
Short Communication	
The relevance of RT-PCR detection of disseminated tumour cells is hampered by the expression of markers regarded as tumour-specific in activated lymphocytes M. Kowalewska, M. Chechlińska, S. Markowicz, P. Kober and R. Nowak	2671

Current Perspective

- Multinational clinical trials in oncology and post-trial benefits for host countries: where do we stand? 2675
M.S. Mano, D.D. Rosa and L. Dal Lago

TuBaFrost

- TuBaFrost 1: Uniting local Frozen Tumour Banks into a European Network: an overview 2678
P.H.J. Riegman, W.N.M. Dinjens, M.H.A. Oomen, A. Spatz, C. Ratcliffe, K. Knox, R. Mager, D. Kerr, F. Pezzella, B. van Damme, M. van de Vijver, H. van Boven, M.M. Morente, S. Alonso, D. Kerjaschki, J. Pammer, J.A. Lopez-Guerrero, A. Llombart Bosch, A. Carbone, A. Gloghini, I. Teodorovic, M. Isabelle, D. Jaminé, A. Passiukov, S. Lejeune, P. Therasse, E.-B. van Veen, K.H. Lam and J.W. Oosterhuis
- TuBaFrost 2: Standardising tissue collection and quality control procedures for a European virtual frozen tissue bank network 2684
M.M. Morente, R. Mager, S. Alonso, F. Pezzella, A. Spatz, K. Knox, D. Kerr, W.N.M. Dinjens, J.W. Oosterhuis, K.H. Lam, M.H.A. Oomen, B. van Damme, M. van de Vijver, H. van Boven, D. Kerjaschki, J. Pammer, J.A. Lopez-Guerrero, A.L. Bosch, A. Carbone, A. Gloghini, I. Teodorovic, M. Isabelle, A. Passiukov, S. Lejeune, P. Therasse, E.-B. van Veen, C. Ratcliffe and P.H.J. Riegman

Reviews

- What clinicians need to know about antioestrogen resistance in breast cancer therapy 2692
A. Milano, L. Dal Lago, C. Sotiriou, M. Piccart and F. Cardoso
- Biology and management of malignant pleural mesothelioma 2706
P.A. Zucali and G. Giaccone

Clinical Oncology

- Sarcomas and malignant phyllodes tumours of the breast – A retrospective study 2715
C. Confavreux, A. Lurkin, N. Mitton, R. Blondet, C. Saba, D. Ranchère, M.-P. Sunyach, P. Thiesse, P. Biron, J.-Y. Blay and I. Ray-Coquard
- Short term psychological distress in patients actively approached for genetic counselling after diagnosis of breast cancer 2722
K.J. Schlich-Bakker, C.C. Wárlám-Rodenhuis, J. van Echtelt, J. van den Bout, M.G.E.M. Ausems and H.F.J. ten Kroode
- Gene expression profilers and conventional clinical markers to predict distant recurrences for premenopausal breast cancer patients after adjuvant chemotherapy 2729
E. Niméus-Malmström, C. Ritz, P. Edén, A. Johnsson, M. Ohlsson, C. Strand, G. Östberg, M. Fernö and C. Peterson
- Patient preference for oral or intravenous chemotherapy: A randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer 2738
P. Pfeiffer, J.P. Mortensen, B. Bjerregaard, L. Eckhoff, K. Schønnemann, E. Sandberg, K. Aabo and A. Jakobsen
- Facial nerve function in carcinoma of the parotid gland 2744
C. Terhaard, H. Lubsen, B. Tan, T. Merks, B. van der Laan, R. Baatenburg-de Jong, H. Manni and P. Knegt
- A feasibility study of the efficacy and tolerability of the combination of Exemestane with the COX-2 inhibitor Celecoxib in post-menopausal patients with advanced breast cancer 2751
P.A. Canney, M.A. Machin and J. Curto

Paediatric Oncology

- Role of radiotherapy and chemotherapy in the risk of secondary leukaemia after a solid tumour in childhood 2757
N. Haddy, M.C. Le Deley, A. Samand, I. Diallo, S. Guérin, C. Guibout, O. Oberlin, M. Hawkins, J.-M. Zucker and F. de Vathaire
- Post-treatment intellectual functioning in children treated for acute lymphoblastic leukaemia (ALL) with chemotherapy-only: A prospective, sibling-controlled study 2765
N.C. Jansen, A. Kingma, A. Schuitema, A. Bouma, J. Huisman, A.J. Veerman and W.A. Kamps

Epidemiology and Cancer Prevention

- Reduced mortality for women with mammography-detected breast cancer in east Denmark and south Sweden 2773
L.H. Christensen, G. Engholm, R. Cortes, J. Ceberg, U. Tange, M. Andersson, A. Bladström, H.T. Mouridsen, T. Möller and H. Storm

Risk of non-Hodgkin's lymphoma and exposure to hexachlorocyclohexane, a nested case-control study V. Rafnsson	2781
Treatment and survival for non-Hodgkin's lymphoma: Influence of histological subtype, age, and other factors in a population-based study (1999–2001) D.P. Cronin-Fenton, L. Sharp, S. Deady and H. Comber	2786
Better quality of life among 10–15 year survivors of Hodgkin's lymphoma compared to 5–9 year survivors: A population-based study F. Mols, A.J.J.M. Vingerhoets, J.W. Coebergh, G. Vreugdenhil, N.K. Aaronson, M.L.M. Lybeert and L.V. van de Poll-Franse	2794
Identification of germline MLH1 alterations in familial prostate cancer H. Fredriksson, T. Ikonen, V. Autio, M.P. Matikainen, H.J. Helin, T.L.J. Tammela, P.A. Koivisto and J. Schleutker	2802
Experimental Oncology	
Childhood acute myelogenous leukaemia: Association between PRAME, apoptosis- and MDR-related gene expression S. Goellner, D. Steinbach, T. Schenk, B. Gruhn, F. Zintl, E. Ramsay and H.P. Saluz	2807
Expression of p16 ^{INK4a} in relation to histopathology and viral load of 'high-risk' HPV types in cervical neoplastic lesions S. Andersson, D. Wangsa, C. Flores-Staino, H. Safari, M. Mints, A. Hjerpe, B. Hagmar and B. Johansson	2815
Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development A. Kruczynski, M. Poli, R. Dossi, E. Chazottes, G. Berrichon, C. Ricome, R. Giavazzi, B.T. Hill and G. Taraboletti	2821
Androgen receptor and vitamin D receptor gene polymorphisms and prostate cancer risk P. Andersson, E. Varenhorst and P. Söderkvist	2833
Pyrazolo[3,4-d]pyrimidines c-Src inhibitors reduce epidermal growth factor-induced migration in prostate cancer cells A. Angelucci, S. Schenone, G.L. Gravina, P. Muzi, C. Festuccia, C. Vicentini, M. Botta and M. Bologna	2838
Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors K. Partheen, K. Levan, L. Österberg and G. Horvath	2846
Calendar of Forthcoming Meetings	I

NUMBER 17

News	2855
Special Section on Pharmacoeconomics	
Editorial Comment	
Did you skip the lectures? J. Cassidy	2860
Economic evaluation of cancer therapies: More and better studies will lead to better choices in cancer care C.A. Uyl-de Groot	2862
Methodological issues in the economic analysis of cancer treatments P. Tappenden, J. Chilcott, S. Ward, S. Eggington, D. Hind and S. Hummel	2867
Health technology assessment in cancer: A personal view from public health N. Waugh	2876
Has NICE been nice to cancer? M. Summerhayes and P. Catchpole	2881

Inequalities in oncology care: Economic consequences of high cost drugs M.G.H. Niezen, E.A. Stolk, A. Steenhoek and C.A. Uyl-De Groot	2887
Short Communication	
Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia T.M. Sissung, K. Mross, S.M. Steinberg, D. Behringer, W.D. Figg, A. Sparreboom and S. Mielke	2893
Position Paper	
Evidence-based treatment of metastatic breast cancer – 2006 recommendations by the AGO Breast Commission G. von Minckwitz, for The Breast Commission of the German Gynaecological Oncology Working Group (AGO)	2897
Current Perspective	
Optimising endocrine approaches for the chemoprevention of breast cancer. Beyond the Study of Tamoxifen and Raloxifene (STAR) Trial V.C. Jordan	2909
TuBaFrost	
TuBaFrost 3: Regulatory and ethical issues on the exchange of residual tissue for research across Europe E.-B. van Veen, P.H.J. Riegman, W.N.M. Dinjens, K.H. Lam, M.H.A. Oomen, A. Spatz, R. Mager, C. Ratcliffe, K. Knox, D. Kerr, B. van Damme, M. van de Vijver, H. van Boven, M.M. Morente, S. Alonso, D. Kerjaschki, J. Pammer, J.A. Lopez-Guerrero, A. Llombart Bosch, A. Carbone, A. Gloghini, I. Teodorovic, M. Isabelle, A. Passiukov, S. Lejeune, P. Therasse and J.W. Oosterhuis	2914
TuBaFrost 4: Access rules and incentives for a European tumour bank J.A. Lopez-Guerrero, P.H.J. Riegman, J.W. Oosterhuis, K.H. Lam, M.H.A. Oomen, A. Spatz, C. Ratcliffe, K. Knox, R. Mager, D. Kerr, F. Pezzella, B. van Damme, M. van de Vijver, H. van Boven, M.M. Morente, S. Alonso, D. Kerjaschki, J. Pammer, A. Carbone, A. Gloghini, I. Teodorovic, M. Isabelle, A. Passiukov, S. Lejeune, P. Therasse, E.-B. van Veen, W.N.M. Dinjens and A. Llombart-Bosch	2924
Reviews	
The role of gene expression profiling in the clinical management of ovarian cancer R.I. Olivier, M. van Beurden and L.J. van't Veer	2930
High-grade glioma in children under 5 years of age: A chemotherapy only approach with the BBSFOP protocol C. Dufour, J. Grill, A. Lellouch-Tubiana, S. Puget, P. Chastagner, D. Frappaz, F. Doz, F. Pichon, D. Plantaz, J.C. Gentet, M.A. Raquin and C. Kalifa	2939
Clinical Oncology	
High inter-observer agreement in immunohistochemical evaluation of HER-2/ <i>neu</i> expression in breast cancer: A multicentre GEPPICS study M. Lacroix-Triki, S. Mathoulin-Pelissier, J.-P. Ghnassia, G. Macgrogan, A. Vincent-Salomon, V. Brouste, M.-C. Mathieu, P. Roger, F. Bibeau, J. Jacquemier, F. Penault-Llorca and L. Arnould	2946
Predictive value of HER-2 and Topoisomerase II α in response to primary doxorubicin in breast cancer E. Arriola, A. Moreno, M. Varela, J.M. Serra, C. Falo, E. Benito and A.P. Escobedo	2954
Rapid assessment breast clinics – Evolution through audit D.P. Toomey, R.A. Cahill, N. Birido, M. Jeffers, B. Loftus, D. McInerney, J. Rothwell and J.G. Geraghty	2961
Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo-controlled study J. Geisler, P.E. Lønning, L.E. Krag, E. Løkkevik, T. Risberg, A.I. Hagen, E. Schlichting, E.A. Lien, E.S. Øjford, G.E. Eide, A. Polli, E. di Salle and J. Paolini	2968
Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma A. Younes, L. Fayad, J. Romaguera, B. Pro, A. Goy and M. Wang	2976
Translation and validation of the SF-36 Health Survey for use among Turkish and Moroccan ethnic minority cancer patients in The Netherlands R. Hoopman, C.B. Terwee, M.J. Muller and N.K. Aaronson	2982

Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: A randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group C.J.A. Punt, S. Suciu, M.A. Gore, J. Koller, W.H.J. Kruit, J. Thomas, P. Patel, D. Lienard, A.M.M. Eggermont and U. Keilholz	2991
---	------

Paediatric Oncology

Histopathological prognostic factors in medulloblastoma: High expression of survivin is related to unfavourable outcome C. Haberler, I. Slavic, T. Czech, E. Gelpi, H. Heinzl, H. Budka, C. Urban, M. Scarpatetti, G. Ebetsberger-Dachs, C. Schindler, N. Jones, A. Klein-Franke, H. Maier, B. Jauk, A. Kiefer and J.A. Hainfellner	2996
--	------

Treatment of high risk medulloblastomas in children above the age of 3 years: A SFOP study J. Verlooy, V. Mosseri, S. Bracard, A.L. Tubiana, C. Kalifa, F. Pichon, D. Frappaz, P. Chastagner, A. Pagnier, A.-I. Bertozzi, J.C. Gentet, E. Sariban, X. Rialland, C. Edan, D. Bours, M. Zerah, C. Le Gales, C. Alapetite and F. Doz	3004
--	------

Epidemiology and Cancer Prevention

Elderly patients with rectal cancer have a higher risk of treatment-related complications and a poorer prognosis than younger patients: A population-based study M.A. Shahir, V.E.P.P. Lemmens, L.V. van de Poll-Franse, A.C. Voogd, H. Martijn and M.L.G. Janssen-Heijnen	3015
---	------

Does marital status and altered contact with the social network predict colorectal cancer survival? M. Villingshøj, L. Ross, B.L. Thomsen and C. Johansen	3022
--	------

Autoimmune diseases, asthma and risk of haematological malignancies: A nationwide case-control study in Sweden K.C. Söderberg, F. Jonsson, O. Winqvist, L. Hagmar and M. Feychting	3028
---	------

Cancer incidence in first-degree relatives of a population-based set of cases of early-onset breast cancer R. Rawal, L. Bertelsen and J.H. Olsen	3034
---	------

Social determinants of access to reference care centres for patients with colorectal cancer – A multilevel analysis S. Blais, O. Dejardin, S. Boutreux and G. Launoy	3041
---	------

Experimental Oncology

Thimet oligopeptidase (EC 3.4.24.15) activates CPI-0004Na, an extracellularly tumour-activated prodrug of doxorubicin V. Dubois, M. Nieder, F. Collot, A. Negrouk, T.T. Nguyen, S. Gangwar, B. Reitz, R. Wattiez, L. Dasnois and A. Trouet	3049
---	------

Human neutrophil peptides 1, 2 and 3 are biochemical markers for metastatic colorectal cancer J. Albrethsen, C.H. Møller, J. Olsen, H. Raskov and S. Gammeltoft	3057
--	------

Mutational analysis of β -catenin and the RAS-RAF signalling pathway in early flat-type colorectal tumours M. Mikami, K. Nosho, H. Yamamoto, T. Takahashi, T. Maehata, H. Taniguchi, Y. Adachi, A. Imamura, M. Fujita, M. Hosokawa, F. Itoh, K. Imai and Y. Shinomura	3065
--	------

Evaluations of vascular disrupting agents CA4P and OXi4503 in renal cell carcinoma (Caki-1) using a silicon based microvascular casting technique H.W. Salmon, C. Mladinich and D.W. Siemann	3073
---	------

Calendar of Forthcoming Meetings	I
----------------------------------	---

NUMBER 18

News	3079
------	------

Position Papers

EACR-19: The best of European cancer research V. Jendrosseck	3084
---	------

Targeting ubiquitin in cancers I. Dikic, N. Crosetto, S. Calatroni and P. Bernasconi	3095
---	------

TuBaFrost

TuBaFrost 5: Multifunctional central database application for a European tumor bank M. Isabelle, I. Teodorovic, M.M. Morente, D. Jaminé, A. Passiukov, S. Lejeune, P. Therasse, W.N.M. Dinjens, J.W. Oosterhuis, K.H. Lam, M.H.A. Oomen, A. Spatz, C. Ratcliffe, K. Knox, R. Mager, D. Kerr, F. Pezzella, M. van de Vijver, H. van Boven, S. Alonso, D. Kerjaschki, J. Pammer, J.A. Lopez-Guerrero, A. Llombart Bosch, A. Carbone, A. Gloghini, E.-B. van Veen, B. van Damme and P.H.J. Riegman	3103
--	------

TuBaFrost 6: Virtual microscopy in virtual tumour banking I. Teodorovic, M. Isabelle, A. Carbone, A. Passiukov, S. Lejeune, D. Jaminé, P. Therasse, A. Gloghini, W.N.M. Dinjens, K.H. Lam, M.H.A. Oomen, A. Spatz, C. Ratcliffe, K. Knox, R. Mager, D. Kerr, F. Pezzella, B. van Damme, M. van de Vijver, H. van Boven, M.M. Morente, S. Alonso, D. Kerjaschki, J. Pammer, J.A. Lopez-Guerrero, A. Llombart Bosch, E.-B. van Veen, J.W. Oosterhuis and P.H.J. Riegman	3110
--	------

Reviews

A nurse is a nurse? A systematic review of the effectiveness of specialised nursing in breast cancer M.R.E. Eicher, S. Marquard and S. Aebi	3117
--	------

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review F.A.L.M. Eskens and J. Verweij	3127
--	------

Clinical Oncology

Mapping the emergence and development of translational cancer research A. Cambrosio, P. Keating, S. Mercier, G. Lewison and A. Mogoutov	3140
--	------

Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance E.A. Rakha, D. Abd El-Rehim, C. Paish, A.R. Green, A.H.S. Lee, J.F. Robertson, R.W. Blamey, D. Macmillan and I.O. Ellis	3149
--	------

Gastrointestinal metastases from primary lung cancer A. Yoshimoto, K. Kasahara and A. Kawashima	3157
--	------

Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: A GOAM phase II randomised study (FOCA trial) A.A. Martoni, C. Pinto, F. Di Fabio, G. Lelli, F.L.R. Limpe, A.L. Gentile, V. Mutri, P. Ballardini, S. Giaquinta and E. Piana	3161
--	------

Equating EORTC QLQ-C30 and FACT-G scores and its use in oncological research B. Holzner, R.K. Bode, E.A. Hahn, D. Cella, M. Kopp, B. Sperner-Unterweger and G. Kemmler	3169
---	------

Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: An EORTC phase III study (10863) L. Beex, C. Rose, H. Mouridsen, J. Jassem, M. Nooij, J. Estape, R. Paridaens, M. Piccart, T. Gorlia, S. Lardenoije and L. Baila	3178
--	------

Paediatric Oncology

Follow-up after childhood cancer: Evaluation of a three-level model C. Eiser, K. Absolom, D. Greenfield, A. Glaser, B. Horne, H. Waite, T. Urquhart, W.H.B. Wallace, R. Ross and H. Davies	3186
---	------

Clinical heart failure in a cohort of children treated with anthracyclines: A long-term follow-up study E.C. van Dalen, H.J.H. van der Pal, W.E.M. Kok, H.N. Caron and L.C.M. Kremer	3191
---	------

Anthracycline-induced cardiotoxicity: Comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials E.C. van Dalen, M. van den Brug, H.N. Caron and L.C.M. Kremer	3199
---	------

Epidemiology and Cancer Prevention

- Reduced folate carrier gene G80A polymorphism is associated with an increased risk of gastroesophageal cancers in a chinese population 3206
 L. Wang, W. Chen, J. Wang, Y. Tan, Y. Zhou, W. Ding, Z. Hua, J. Shen, Y. Xu and H. Shen
- Trends in stomach cancer mortality in relation to living conditions in childhood. A study among cohorts born between 1860 and 1939 in seven European countries 3212
 M. Amiri, A.E. Kunst, F. Janssen and J.P. Mackenbach
- Polymorphisms in the E-cadherin (CDH1) gene promoter and the risk of bladder cancer 3219
 L.A. Kiemeneij, K.P. van Houwelingen, M. Bogaerts, J.A. Witjes, D.W. Swinkels, M. den Heijer, B. Franke, J.A. Schalken and G.W. Verhaegh
- Generalisability of survival estimates for patients with breast cancer – A comparison across two population-based series 3228
 J. Lundin, T. Lehtimäki, M. Lundin, K. Holli, L. Elomaa, T. Turpeenniemi-Hujanen, V. Kataja, J. Isola and H. Joensuu
- Estimating regional cancer burden in countries with partial registration coverage: An application to all malignant neoplasms in Italy over the period 1970–2010 3236
 E. Grande, R. Inghelmann, S. Francisci, A. Verdecchia, A. Micheli, R. Capocaccia and R. De Angelis

Experimental Oncology

- Up-regulation of gelatinases in the colorectal adenoma-carcinoma sequence 3246
 A.Z. Gimeno-García, A. Santana-Rodríguez, A. Jiménez, A. Parra-Blanco, D. Nicolás-Pérez, C. Paz-Cabrera, F. Díaz-González, C. Medina, L. Díaz-Flores and E. Quintero
- Hyaluronectin modulation of lung metastasis in nude mice 3253
 S. Paris, R. Sesboüé, C. Chauzy, C. Maingonnat and B. Delpéch
- Growth inhibition and apoptosis by (–)-epicatechin gallate are mediated by cyclin D1 suppression in head and neck squamous carcinoma cells 3260
 Y.C. Lim, S.-H. Lee, M.H. Song, K. Yamaguchi, J.-H. Yoon, E.C. Choi and S.J. Baek
- Tissue inhibitor of metalloproteinase-3 induces apoptosis in prostate cancer cells and confers increased sensitivity to paclitaxel 3267
 X. Deng, S. Bhagat, Z. Dong, C. Mullins, S.R. Chinni and M. Cher
- Gene expression profile analysis of an isogenic tumour metastasis model reveals a functional role for oncogene AF1Q in breast cancer metastasis 3274
 D.-Q. Li, Y.-F. Hou, J. Wu, Y. Chen, J.-S. Lu, G.-H. Di, Z.-L. Ou, Z.-Z. Shen, J. Ding and Z.-M. Shao
- Dexamethasone inhibits TRAIL-induced apoptosis of thyroid cancer cells via Bcl-x_L induction 3287
 A. Petrella, S.F. Ercolino, M. Festa, A. Gentilella, A. Tosco, S.D. Conzen and L. Parente
- Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies 3294
 E.M. Kemper, W. Leenders, B. Küsters, S. Lyons, T. Buckle, A. Heerschap, W. Boogerd, J.H. Beijnen and O. van Tellingen
- The effect of hyperbaric oxygen therapy on tumour growth in a mouse model of colorectal cancer liver metastases 3304
 J. Daruwalla and C. Christophi

- Referees 2006** 3312
- List of Contents, Volume 42, 2006** 3314
- Author Index, Volume 42, 2006** 3345
- Calendar of Forthcoming Meetings** I

SUPPLEMENT 1

4th International Conference
Cancer Prevention 2006
Advances in Molecular and Clinical Aspects of Cancer Prevention

SUPPLEMENT 2

5th European Breast Cancer Conference
Nice – France
21–25 March 2006

SUPPLEMENT 3

Gastrointestinal Stromal Tumours:
Perspectives on Current Diagnosis and Therapy
Guest Editor: Charles D. Blanke, MD

SUPPLEMENT 4

Breast cancer:
The beginning of the end or the end of the beginning

SUPPLEMENT 5

From the 28th Annual
San Antonio Breast Cancer Symposium into clinical practice
What does it mean for our patients?

SUPPLEMENT 6

2nd International Congress on Molecular Staging of Cancer
22–26 June 2006

SUPPLEMENT 7

Bringing Discovery to Light Proceedings of an official Satellite Symposium at the 13th European
Cancer Conference (ECCO)
Paris, 2005

SUPPLEMENT 8

Optimizing outcomes
Experience with ibandronate
In metastatic bone disease and bone pain

SUPPLEMENT 9

Proceedings of the satellite symposium
'The quiet revolution in breast cancer treatment:
how aromatase inhibitors are displacing tamoxifen' at
ECCO 13, 30 October 2005, Paris, France
Guest Editors: Matthew J. Ellis and Alain Monnier

SUPPLEMENT 10

New horizons for gastric cancer
Proceedings of a satellite symposium held in conjunction with
the 8th World Congress on Gastrointestinal Cancer,
Barcelona, Spain
29 June 2006

SUPPLEMENT 11

Electrochemotherapy
Guest Editor: Lluís M. Mir D.Sc.

SUPPLEMENT 12

18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Prague, Czech Republic
7–10 November 2006

SUPPLEMENT 13

Road Map to Interpreting Breast Cancer Data In 2006 and Beyond
Based on Proceedings from the Lilly Oncology Satellite Symposium
held at the 5th European Breast Cancer Conference
21st March 2006, Nice, France